What is HC Wainwright’s Forecast for MNPR FY2024 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Monopar Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the company will earn ($1.68) per share for the year, up from their prior forecast of ($2.06). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Separately, Rodman & Renshaw initiated coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $18.09 on Thursday. The stock’s 50 day simple moving average is $8.79 and its 200 day simple moving average is $5.19. Monopar Therapeutics has a one year low of $1.37 and a one year high of $38.50. The firm has a market cap of $95.52 million, a PE ratio of -9.25 and a beta of 1.09.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

Insider Transactions at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.